Phase 3
Completed N=214
Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
Type II Diabetes Mellitus · Dyslipidemia
Source: ClinicalTrials.gov NCT00344370 ↗
Enrolled (actual)
214
Serious AEs
6.1%
Results posted
Jan 2010
Primary outcomePrimary: NCEP LDL-C Target Attainment — 110; 55 Participants
Summary
This is a sixteen-week double-blind active-controlled follow-on and 28-week single-blind extension study for patients who participated in study NK-104-305.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY NCEP LDL-C Target Attainment |
110; 55 | — |
| SECONDARY Percent Change From Baseline in LDL-C |
-40.98; -41.43 | — |
Eligibility Criteria
Inclusion Criteria
- Type II diabetes mellitus
- Combined dyslipidemia
- Completed NK-104-305 (NCT00309751)
Exclusion Criteria
- Withdrawal from NK-104-305 (NCT00309751)
Data sourced from ClinicalTrials.gov (NCT00344370). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.